	2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	267	338	451	519	584	700	831	976	1,092	1,009	1,395	1,691	1,908	2,218	2,538	2,620
Cost of Operating Revenue	160	203	266	294	324	384	437	518	638	625	813	944	1,063	1,274	1,486	1,539
Gross Profit	106	135	185	225	260	316	394	458	454	384	582	748	845	945	1,053	1,081
Gross Margin	39.8	39.9	41.1	43.4	44.6	45.2	47.4	46.9	41.6	38.0	41.7	44.2	44.3	42.6	41.5	41.2
Total Operating Expenses	249	321	449	482	543	652	783	938	1,072	1,046	1,317	1,558	1,755	2,046	2,316	2,404
Operating Profit	17	17	3	37	41	48	47	38	20	-37	77	134	153	172	222	216
Operating Margin	6.6	5.0	0.6	7.1	7.0	6.9	5.7	3.8	1.9	-3.6	5.5	7.9	8.0	7.8	8.8	8.3
Financing Income/(Expense) - Net	-23	-28	-30	-32	-36	-15	-37	-67	-134	-110	-87	-94	-99	-141	-169	-171
Profit before Taxes	-3	-10	-27	3	0	35	27	-33	-119	-229	88	45	68	57	27	40
Income Taxes	0	1	5	-2	-2	12	10	-3	6	-8	49	27	26	8	4	7
Profit after Tax	-3	-11	-36	1	-1	22	21	-25	-107	-193	54	29	48	44	14	23
PAT Margin	-1.2	-3.1	-7.9	0.2	-0.3	3.2	2.5	-2.5	-9.8	-19.2	3.9	1.7	2.5	2.0	0.5	0.9
EPS - Basic - ex Extraordinary Items	-0.39	-1.23	-4.15	0.12	-2.43	2.68	2.37	-2.80	-11.98	-16.92	4.12	2.10	3.44	3.17	0.97	1.55
EPS - Diluted - ex Extraordinary Items	-0.39	-1.23	-4.15	0.11	-2.43	2.68	2.37	-2.80	-11.98	-16.92	3.95	2.09	3.41	3.12	0.97	1.55
EBIT	17	17	3	37	41	48	47	38	20	-37	77	134	153	172	222	216
EBITDA	41	47	39	78	85	105	119	123	169	122	236	297	327	384	466	473
EBITDA Margin	15.5	13.8	8.6	14.9	14.6	15.0	14.3	12.6	15.5	12.1	16.9	17.6	17.1	17.3	18.4	18.1

Balance Sheet

Abridged

Understanding Balance Sheet

Healthcare Global Enterprises Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	84	155	110	113	227	244	220	273	304	435	502	580	680	844	1,135
Long-Term Investments	0	0	0	0	4	4	5	11	7	6	6	7	7	7	7
Property Plant & Equipment - Net	381	429	445	484	640	765	887	1,004	1,551	1,295	1,358	1,371	1,589	1,988	2,060
Total Non-Current Assets	422	554	579	645	816	982	1,224	1,381	1,949	1,601	1,717	1,736	2,028	2,699	2,787
Total Assets	506	709	689	758	1,044	1,226	1,444	1,654	2,253	2,036	2,220	2,316	2,707	3,543	3,923
Total Current Liabilities	137	156	149	184	263	366	359	547	576	465	470	570	744	1,046	1,017
Long Term Debt	135	239	252	266	246	283	372	517	1,139	815	829	815	1,044	1,380	1,359
Total Non-Current Liabilities	150	257	257	366	322	371	506	584	1,258	856	866	876	1,099	1,507	1,495
Total Liabilities	287	413	407	550	585	736	865	1,131	1,833	1,322	1,336	1,447	1,842	2,553	2,512
Total Shareholders' Equity	211	283	264	182	426	433	515	477	381	697	870	861	826	922	1,332
Minority Interest	8	13	18	25	33	57	64	46	39	17	13	9	39	68	78
Total Equity	219	296	282	208	459	490	579	522	420	714	884	869	865	990	1,410
Total Liabilities & Equity	506	709	689	758	1,044	1,226	1,444	1,654	2,253	2,036	2,220	2,316	2,707	3,543	3,923

Cash Flow

Abridged

Understanding Cash Flow Statement

Healthcare Global Enterprises Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	18.80	16.57	19.12	42.60	41.24	85.69	79.98	41.73	40.07	65.66	151.08	208.42	202.88	244.90	234.60
Working Capital - Increase/(Decrease)	-19.37	-10.81	5.72	-10.17	-1.91	-12.06	-13.39	7.41	-22.65	-50.71	-10.52	-45.87	-27.19	-76.50	-42.56
Net CF from Operating Activities	-0.56	5.75	24.85	32.44	39.33	73.63	66.59	49.14	17.42	14.95	140.56	162.55	175.69	168.40	192.04
Capital Expenditures - Net	46.20	89.40	50.49	80.12	209.84	192.34	255.99	188.58	107.39	35.36	70.44	125.68	183.98	207.32	288.49
Net CF from Investing Activities	-46.47	-197.48	-12.88	-82.83	-205.82	-213.48	-285.58	-240.51	-103.19	-178.25	110.89	-139.60	-233.93	-497.20	-189.39
Stock - Issuance/(Retirement) - Net	43.31	80.00	15.00	10.00	271.27	6.93	34.81	0.09	20.32	519.44	132.16	0.89	1.95	1.56	448.85
Debt - LT & ST - Issuance/(Retirement) - Total	14.08	96.39	-20.82	44.75	-18.61	92.13	149.25	129.54	18.12	-205.98	-182.80	-45.34	93.33	118.36	-36.96
Net Cash Flow from Financing Activities	57.90	165.44	1.00	51.90	251.71	110.48	196.39	135.19	56.10	224.96	-61.62	-44.46	53.08	115.72	407.65
Free Cash Flow to Equity	-32.68	12.75	-46.46	-2.93	-189.12	-26.58	-40.16	-9.90	-71.85	-226.39	-112.68	-8.47	85.04	79.44	-133.41
Free Operating CF net dividend	-46.77	-83.71	-25.86	-47.76	-170.94	-119.03	-189.57	-139.64	-90.39	-20.47	69.33	29.31	-9.99	-40.47	-100.06
Free Operating CF	-46.77	-83.71	-25.86	-47.76	-170.94	-119.03	-189.57	-139.64	-90.39	-20.47	69.33	29.31	-9.99	-40.47	-100.06

Business Segment Analysis

FY End:

Mar 26

Healthcare Global Enterprises Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Setting up and Managing Hospitals and Medical Diagnostic services (100.0%)₹ 292.10 Cr

Revenue / Sales

Setting up and Managing Hospitals and Medical Diagnostic services (100.0%)₹ 2,538.43 Cr

Assets

Setting up and Managing Hospitals and Medical Diagnostic services (100.0%)₹ 3,922.53 Cr

Operating Income

Setting up and Managing Hospitals and Medical Diagnostic services (100.0%)₹ 222.16 Cr

Regional Segment Analysis

FY End:

Mar 26

Healthcare Global Enterprises Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (97.1%)₹ 2,464.41 CrOuside India (2.9%)₹ 74.02 Cr

Historical Segment Analysis

Track how Healthcare Global Enterprises Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Setting up and Managing Hospitals and Medical Diagnostic services	108	35	71	133	186	209	292

Frequently Asked Questions

What is the revenue of Healthcare Global Enterprises Ltd.?

The latest trailing twelve month revenue of Healthcare Global Enterprises Ltd. is ₹ 2,620.02 Cr, reflecting a 1-year growth of 13.65% and a 3-year CAGR of 14.53%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Healthcare Global Enterprises Ltd.?

The latest trailing twelve month net profit (PAT) of Healthcare Global Enterprises Ltd. is ₹ 22.78 Cr, with a 3-year earnings CAGR of -11.02%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Healthcare Global Enterprises Ltd.?

The trailing twelve month EBITDA of Healthcare Global Enterprises Ltd. is approximately ₹ 216.25 Cr (based on an operating margin of 8.25%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Healthcare Global Enterprises Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Healthcare Global Enterprises Ltd. is 1.55. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Healthcare Global Enterprises Ltd.?

The debt-to-equity ratio of Healthcare Global Enterprises Ltd. stands at 1.30. The interest coverage ratio is 1.26x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Healthcare Global Enterprises Ltd.?

The estimated book value per share of Healthcare Global Enterprises Ltd. is 89.21 (derived from a P/B ratio of 7.73 and market price of ₹ 689.65), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Healthcare Global Enterprises Ltd.?

The trailing twelve month operating cash flow of Healthcare Global Enterprises Ltd. is ₹ 192.04 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Healthcare Global Enterprises Ltd. report consolidated or standalone financials?

Healthcare Global Enterprises Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.